Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: a Longitudinal Analysis of REPRIEVE data.

Emma M Kileel,Carlos D Malvestutto,Janet Lo,Kathleen V Fitch,Carl J Fichtenbaum,Judith A Aberg,Markella V Zanni,Esteban Martinez,Nwora Lance Okeke,Princy Kumar,Esau Joao,Sara H Bares, Daniel Berner,Marek Smieja, Jhoanna C Roa,Sara McCallum,Pamela S Douglas,Heather J Ribaudo,Steven K Grinspoon

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）

引用 1|浏览34

暂无评分

摘要

Weight gain with longer-term INSTI-based regimens remains unknown. Over 2-years of follow-up in REPRIEVE, INSTI use was associated with weight gain among those on an INSTI entry regimen <2 years [+0.27 (0.22, 0.33) vs. 0.17 (0.12, 0.23) kg/m2/year, p=0.01], but not those on an INSTI regimen >2 years at entry.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要